CIK 0001601485 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Elicio Therapeutics, Inc.
Sign in to watch- Ticker
- ELTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 113430072
- Phone
- (857) 209-0050
- Business address
- 451 D STREET, 5TH FLOOR, BOSTON, MA, 02210
- Former names
- Angion Biomedica Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-09 | DeMuth Peter Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −362 | 0 | ||
| 2025-06-03 | Chudnovsky Yekaterina Director | Grant or award · Warrant (right to buy) | +103,225 | 103,225 | ||
| 2025-05-19 | Ashe Carol Gail Director | Grant or award · Stock Option (Right to Buy) | +7,900 | 7,900 | ||
| 2025-05-19 | Nissenson Allen Director | Grant or award · Stock Option (Right to Buy) | +7,900 | 7,900 | ||
| 2025-05-19 | Venkatesan Jay Director | Grant or award · Stock Option (Right to Buy) | +7,900 | 7,900 | ||
| 2025-05-19 | ADAMS JULIAN Director | Grant or award · Stock Option (Right to Buy) | +7,900 | 7,900 | ||
| 2025-05-19 | WILSON KAREN J Director | Grant or award · Stock Option (Right to Buy) | +7,900 | 7,900 | ||
| 2025-05-19 | RUFFOLO ROBERT R Director | Grant or award · Stock Option (Right to Buy) | +7,900 | 7,900 | ||
| 2025-05-19 | Chudnovsky Yekaterina Director | Grant or award · Stock Option (Right to Buy) | +7,900 | 7,900 | ||
| 2025-04-15 | Shah Preetam See Remarks | Grant or award · Stock Option (Right to Buy) | +191,624 | 191,624 | ||
| 2025-03-05 | Chudnovsky Yekaterina Director | Conversion | +3,500,573 | $5.81 | $20.3M | 5,416,212 |
| 2025-03-05 | Chudnovsky Yekaterina Director | Conversion · Convertible Note (convertible into Common Stock) | −3,442,341 | $5.81 | $20.0M | 0 |
| 2025-02-03 | DeMuth Peter Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +44,400 | 44,400 | ||
| 2025-02-03 | Haqq Christopher See Remarks | Grant or award · Stock Option (Right to Buy) | +44,000 | 44,000 | ||
| 2025-02-03 | Connelly Robert CEO, President and Director | Grant or award · Stock Option (Right to Buy) | +121,600 | 121,600 | ||
| 2024-12-16 | DeMuth Peter Chief Scientific Officer | Option exercise | +381 | $4.41 | $2K | 381 |
| 2024-12-16 | DeMuth Peter Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −381 | 0 | ||
| 2024-11-26 | Venkatesan Jay Director | Option exercise | +50,000 | $0.01 | $500 | 179,581 |
| 2024-11-26 | Venkatesan Jay Director | Option exercise · Warrant to Purchase Common Stock | −50,000 | 0 | ||
| 2024-11-21 | WILSON KAREN J Director | Grant or award · Stock Option (Right to Buy) | +4,100 | 4,100 |
Page 2 of 9 · 171 trades